Douglas Ward
Chief Executive Officer at LUMOS DIAGNOSTICS HOLDINGS LIMITED
Net worth: 11 690 $ as of 2024-05-30
Douglas Ward active positions
| Companies | Position | Start | End |
|---|---|---|---|
| LUMOS DIAGNOSTICS HOLDINGS LIMITED | Director/Board Member | 2023-07-12 | - |
| Chief Executive Officer | 2022-06-20 | - |
Career history of Douglas Ward
Former positions of Douglas Ward
| Companies | Position | Start | End |
|---|---|---|---|
Personal Genome Diagnostics, Inc.
 Personal Genome Diagnostics, Inc. BiotechnologyHealth Technology Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD. | Chief Executive Officer | 2016-05-08 | 2020-04-20 |
| HOLOGIC, INC. | Corporate Officer/Principal | - | - |
Training of Douglas Ward
| Ohio Wesleyan University | Undergraduate Degree |
Statistics
International
| United States | 4 |
| Australia | 2 |
Operational
| Chief Executive Officer | 2 |
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| LUMOS DIAGNOSTICS HOLDINGS LIMITED | Health Technology |
| HOLOGIC, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Personal Genome Diagnostics, Inc.
Personal Genome Diagnostics, Inc. BiotechnologyHealth Technology Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD. | Health Technology |
- Stock Market
- Insiders
- Douglas Ward
- Experience
